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 i 
Abstract 
It is known that hibernating animals display a drastic reduction in metabolic rate, 
accompanied by reduced heart rate and rate of blood flow through vessels. Sluggish 
blood flow increases the risk for developing clots, yet it has been observed that 
hibernators conclusively display elongated clotting times. This observed impairment 
may be caused by the decrease in body temperature, due to a negative impact on the 
functioning of the enzymes involved in coagulation. Some hibernating endotherms, or 
“warm-blooded” animals, employ biological mechanisms as preventative means to 
prevent clotting during hibernation, such as the down-regulation of certain clotting 
factors or the production of an inhibitor. In this study, the hemostatic properties of 
ectotherms, or “cold-blooded” animals, were studied by comparing the clotting times of 
non-hibernating and hibernating American bullfrogs (Rana catesbeiana) using activated 
partial thromboplastin time (aPTT). It was found that blood coagulation in ectotherms is 
less impacted by the change in temperature than in endotherms, and that the 
difference in clotting time between non-hibernating and hibernating frogs could not be 
explained by temperature alone. Bullfrogs appear to down-regulate levels of 
coagulation factors XI and XII, as well as produce a non-protein coagulation inhibitor. 
These results suggest that hibernating ectotherms such as frogs employ similar 
physiological mechanisms to prevent clotting during hibernation as do endotherms.  
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 1 
Introduction 
During hibernation, animals display a significant reduction in metabolic rate and 
heart rate, which consequently slows the rate of blood flow through vessels. Sluggish 
circulation puts hibernators at higher risk for developing unwanted blood clots. 
However, it has been shown that animals in hibernation conclusively display elongated 
coagulation times compared to those in a non-hibernating state, likely as a preventative 
measure to protect against increased clotting risk. Most research into the effects of 
hibernation on coagulation has been focused on endotherms, “warm-blooded” animals 
that maintain a constant internal temperature (mammals and birds), rather than 
ectotherms, “cold-blooded” animals whose internal temperature is primarily dependent 
on the temperature of their environment (amphibians, reptiles, fish, insects, and 
arachnids). The goal of this study is to determine whether ectothermic mechanisms for 
preventing clotting during hibernation are similar to those which have been found in 
endotherms. Using the American bullfrog, Rana catesbeiana, as a model, I examined the 
role of temperature in causing elongated clotting and identified physiological changes in 
the hemostatic system during hibernation. This study seeks to provide a greater 
understanding of how hibernation affects hemostasis in this understudied groups of 
animals.   
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Literature Review 
Hemostasis 
Hemostasis refers to the process of stopping blood flow following vascular 
damage by the formation of a clot. This system must be highly regulated in order to 
maintain a constant balance between excessive clotting and insufficient clotting, as both 
can be deadly. Too much clotting causes the formation of thrombi, which can occlude 
vessels or break off and travel to the heart, brain, or lungs. Too little clotting causes 
hemorrhaging, the uncontrolled loss of blood. The process of hemostasis is 
characterized by four components: primary hemostasis, secondary hemostasis, fibrin 
clot formation and stabilization, and fibrinolysis. 
Primary hemostasis is the formation of a platelet plug. It is stimulated by an 
injury to the epithelial lining on the inside of a blood vessel that exposes the underlying 
collagen [1]. Adhesion, the first step in this process, occurs when exposed collagen 
triggers the release of chemicals that induce vasoconstriction [2,3], the narrowing of 
blood vessels, to reduce blood flow to the area, and cause circulating platelets to adhere 
to the damaged epithelium. This is followed by aggregation, in which these platelets 
initiate a positive feedback loop by releasing chemicals that attract additional platelets, 
ultimately leading to the formation of a platelet plug [1,3,4]. The platelet plug is an 
unstable and temporary means to stem blood loss, and must be reinforced by a stable, 
permanent clot produced by secondary hemostasis. 
Secondary hemostasis, also known as the coagulation cascade, involves a series 
of enzymatic reactions which produce amplified amounts of product at each step. The 
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proteins in the blood that are involved in the coagulation cascade are called coagulation 
factors. These factors are produced by the liver [2] and circulate in the blood as 
zymogens, inactive enzyme precursors that require a biochemical change to become 
active. Each step in the cascade activates a zymogen, which in turn can activate an 
increasing amount of the next zymogen in the process [5]. This amplification ultimately 
results in the formation of a stable fibrin clot. It should also be noted that platelets play 
an important role in secondary hemostasis, as they provide the surface on which these 
zymogen reactions occur [1,6]. 
Traditionally, the coagulation cascade has been divided into three pathways: the 
extrinsic pathway, the intrinsic pathway, and the common pathway. The extrinsic 
pathway is initiated by chemicals external to the blood vessel that are released from 
damaged tissues. The intrinsic pathway, however, initiates coagulation when damage is 
within the blood vessel, and all necessary components are present in the circulating 
blood [2]. The extrinsic pathway does not act exclusive to the intrinsic pathway. Recent 
research indicates that the extrinsic pathway is involved in clot initiation, while the 
intrinsic pathway is responsible for clot growth [4,5,7]. However, the intrinsic pathway 
may act alone when the endothelial lining is damaged but the blood vessel wall has not 
been broken. Both pathways converge at the activation of coagulation factor X, the 
point at which the common pathway begins (Fig. 1).  
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Figure 1 - Secondary Hemostasis and Fibrin Clot Formation & Stabilization 
 
Due to the complex nature of the coagulation cascade and its pathways, it is 
helpful to think of secondary hemostasis as three phases: initiation, amplification, and 
propagation. Initiation begins via the extrinsic pathway when damaged tissues release a 
protein called tissue factor (TF), also known as coagulation factor III [4,6,7]. Tissue factor 
is unique in that it is always present in its activated form and it is thought to be essential 
to life [5,8]. Tissue damage also causes the activation of another coagulation factor in 
the blood, factor VII, which combines with TF to form the TF-VIIa complex. The “a” 
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notation indicates an activated enzyme. One function of this complex is to activate 
factor X to factor Xa and begin the common pathway (Fig. 1). Under normal 
physiological circumstances, the extrinsic pathway is the primary means for the 
initiation of coagulation [2,8]. 
Coagulation may also be initiated by the intrinsic pathway, and is triggered by 
the appearance of negatively charged areas within the vessel when the epithelial lining 
is damaged. Contact with these areas results in the activation of coagulation factor XII to 
factor XIIa [2,5,7]. The cascade proceeds as follows: factor XIIa activates factor XI, factor 
XIa activates factor IX, and factor IXa complexes with factor VIIIa. The factor IXa-factor 
VIIIa complex catalyzes the conversion of factor X to factor Xa, the first enzyme in the 
common pathway [1] (Fig. 1).  
In addition to beginning the common pathway, the activation of factor Xa is the 
first step in the propagation phase. In this phase, factor Xa joins with factor Va to form 
the prothrombinase complex. The role of the prothrombinase complex is to catalyze the 
conversion of prothrombin (factor II) to thrombin (factor IIa) [5]. The production of 
thrombin is the key event in the coagulation cascade [9]; once it has been formed, the 
amplification phase can begin. This phase is characterized by the positive feedback on 
the system initiated by thrombin. Thrombin is capable of activating zymogens earlier in 
the intrinsic and common pathways. These include factor XI, factor VIIIa, and factor V, as 
well as the activation of additional platelets [6]. The combined role of the propagation 
and amplification phases is to produce sufficient thrombin to generate widespread clot 
formation [6]. 
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The generation of thrombin triggers the third major event in coagulation, fibrin 
clot formation and stabilization. The role of thrombin is to convert fibrinogen (factor I), a 
soluble blood protein, to fibrin (factor Ia), which forms polymers and becomes insoluble 
[4]. Fibrin makes up the molecular scaffolding of a clot. Factor XIII, activated by 
thrombin to factor XIIIa, cross-links the long fibrin strands over top of the unstable 
platelet plug produced by primary hemostasis, stabilizing it [3] (Fig. 1).  
Once a clot is no longer needed, fibrinolysis takes place to return normal blood 
flow to the area. To begin this process, endothelial cells on the inside of the blood vessel 
release a protein called tissue plasminogen activator (tPA). The role of tPA is to catalyze 
the conversion of plasminogen to plasmin, the major enzyme responsible for fibrin clot 
degradation [4]. To constantly maintain hemostasis, organisms must employ a complex 
combination of primary hemostasis, secondary hemostasis, and fibrinolysis. 
 
Hibernation 
Many organisms are capable of entering a state of dormancy, also called torpor, 
when environmental conditions are less than optimal. This state of dormancy is 
characterized by a marked reduction in metabolic activity. Aestivation is one type of 
torpor used by some organisms, and takes place during the summer months when 
conditions are hot and dry. Aestivation protects the organism from damage caused by 
high temperatures and from the risk of desiccation [10] and is common in mollusks, 
arthropods, fish, amphibians, and reptiles. Some small desert mammals have also been 
shown to use this adaptation [11]. 
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On the other end of the spectrum, hibernation is an adaptation for winter 
months, when temperatures are cold and food can be scarce. This dormancy period is 
characterized by a significant reduction in heart rate, breathing rate, body temperature 
and metabolism. Preparation for hibernation is marked by an increase in stores of fat 
and glycogen that are depleted over the course of the winter [12,13]. Hibernation has 
also been shown to inhibit the immune system [14,15]. A large portion of the current 
understanding about hibernation is based on studies of mammalian hibernation, but it is 
also observed in reptiles, amphibians, insects, and birds. Preparation for, and 
maintenance of, hibernation requires a complex series of biochemical changes that are 
still not completely understood. 
The overall reduction in body temperature may be expected to play a significant 
role in hibernation physiology [16,17], as the Q10, or temperature sensitivity factor, for 
biological processes is approximately 2-3 [12]. This means that for every 10 degree 
change in temperature, the rate of reaction changes by a factor of 2-3. Therefore, as 
hibernating animals get increasingly colder, various metabolic enzymes become 
increasingly inefficient.  
In addition, hibernation is accompanied by a strong suppression of transcription 
and translation [12,16]. Transcription is the process of making a copy of a sequence in 
the genome, and translation is the process of turning that copy into a new protein 
molecule. Reducing these processes during hibernation is beneficial, as they are 
energetically expensive to carry out. However, not all proteins are down-regulated, 
some are expressed in higher amounts during hibernation. For example, the enzyme 
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pancreatic lipase is responsible for breaking down fats into free fatty acids that can be 
used for energy, which is necessary when the organism is relying on fat stores for its 
survival [12]. This study examines how these two key aspects of hibernation, decreased 
temperature and changes in protein expression, impact the hemostatic system of the 
American bullfrog.  
 
Hibernation & Hemostasis 
The metabolic depression seen during hibernation affects the cardio-circulatory 
system by reducing heart rate and subsequently reducing the rate of blood flow through 
vessels [18]. Decreased temperature also contributes to reduced blood flow by 
increasing blood viscosity [19]. Sluggish circulation leads to an increased risk of forming 
an unwanted intravascular clot. It was observed as early as the 18th century that 
animals in hibernation have extended clotting times, and this is probably an adaptive 
mechanism used to compensate for the increased risk of forming clots [20].   
The reduction in temperature itself would predict an impairment in coagulation, 
as the clotting factors, which are enzymes, would be expected to work less efficiently at 
increasingly colder temperatures. Recall that the Q10 (temperature sensitivity factor) for 
most biological processes is 2-3, meaning that they work faster as temperature 
increases and slower as temperature decreases. Indeed, non-hibernating animals 
exposed to hypothermic conditions have demonstrated extended clotting times, as 
measured by both prothrombin time (PT) and activated partial thromboplastin time 
(aPTT) [21]. These laboratory tests are used to measure the integrity of the extrinsic (PT) 
and intrinsic (aPTT) pathways. Hypothermia appears to cause a delay in the initiation of 
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thrombin, but it has no effect on the propagation phase and therefore the ultimate 
strength of the clot [21,22]. Hypothermic conditions have also been shown to cause 
platelet dysfunction by decreasing both platelet count and aggregability [19,22,23]. 
In addition to the impact of temperature, blood coagulability can be reduced 
when organisms alter the expression of certain types of proteins. One strategy is to 
down-regulate the production of certain coagulation factors. Hibernating hamsters and 
ground squirrels both display a reduction in the amount factor V from the common 
pathway, as well as a marked reduction in the amount of prothrombin (factor II) present 
in their blood [24,25,26,27]. Hamsters have also been shown to suppress production of 
factor VII of the extrinsic pathway [24].   
Another strategy is to up-regulate the production of a clotting inhibitor. Ground 
squirrels have been shown to upregulate the production of the plasma protein α2-
macroglobulin. α2-Macroglobulin is a broad spectrum inhibitor of enzymes, known as 
proteases, that break apart bonds in proteins [20]. It has been shown to be a particularly 
potent inhibitor of factor Xa, the enzyme which begins the common pathway [20]. 
Hedgehogs display a rise in the number of mast cells, also called heparinocytes, which 
produce the endogenous anticoagulant heparin [28]. Heparin increases the activity of 
the regulatory protein antithrombin. As its name suggests, the role of antithrombin is to 
inhibit thrombin, preventing clotting by preventing the formation of fibrin strands. In 
cats [29], bats, turtles [30], and dogs [23] there appears to be an increase in heparin or 
another heparin-like substance, but no increase in mast cells. This study seeks to 
determine whether ectothermic animals employ similar mechanisms for preventing 
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coagulation during hibernation as those observed in endotherms, and to compare the 
impact of temperature on clotting in these two groups of animals.  
 
Materials & Methods 
Twenty-two American Bullfrogs, Rana catesbeiana, were obtained from Kons 
Scientific (Germantown, WI). The average weight of each frog was 220.2 grams. Five 
frogs were randomly selected to serve as a control group and kept at room temperature 
in a plastic tub with a ventilated lid filled with approximately 2-3 inches of tap water. 
The remaining seventeen frogs were separated into three groups, A, B, and C, to be kept 
in hibernation for increasing lengths of time. They were kept in three additional tubs 
and placed in an environmental chamber on September 30th, 2014. To best mimic the 
natural process of hibernation, the temperature of the chamber was decreased steadily 
at a rate of three degrees every three days until it reached 3°C (on October 23rd, 2014). 
No group of frogs was fed during this time. 
Blood was drawn from the five room temperature frogs on October 23rd, 2014. 
An anesthetic solution was prepared using tricaine mesylate, more commonly known as 
MS-222, in a ratio of 2.5g MS-222 per liter of water. The resulting solution was mildly 
acidic (pH ~ 5), and was buffered using sodium bicarbonate to a neutral pH of 
approximately 7-7.5. Individually, frogs were placed into the anesthetic solution until 
rendered immobile, typically about 2-3 minutes, and then weighed. To expose the heart, 
a vertical incision was made on the ventral side of the frog, just to the right of the 
sternum. Using a syringe flushed with 0.105M (3.2%) sodium citrate (to prevent 
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coagulation upon withdrawal), blood was drawn by cardiac puncture (Fig. 2). The blood 
was placed into centrifuge tubes and centrifuged for 5 minutes at 2500g to separate the 
plasma from the blood cells. The plasma, containing the coagulation factors, was then 
pipetted into new centrifuge tubes in 0.5mL amounts and stored at -80°F. 
 
Figure 2 - Drawing blood from  Rana catesbeiana by cardiac puncture 
 
Blood was drawn from the first group of hibernating frogs (A) on October 30th, 
2014, one week after hibernation temperature was reached. Plasma was obtained from 
5 frogs. Blood was drawn from the second group of hibernating frogs (B) on November 
13th, 2014, three weeks after hibernation temperature was reached. Plasma was 
obtained from 5 frogs. Finally, blood was drawn from the last group of hibernating frogs 
(C) on December 4th, 2014, six weeks after hibernation temperature was reached. 
Plasma was obtained from the remaining 7 frogs.  
Laboratory tests were performed throughout the spring 2015 semester. 
Evaluation of the integrity of the intrinsic pathway was performed by measuring 
activated partial thromboplastin time (aPTT), using the KC1Δ Amelung coagulation 
analyzer.  
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Effect of Temperature on Coagulation 
To investigate the effects of temperature on coagulation, three groups were 
compared: room temperature frogs, hibernating frogs, and an endotherm (sheep). To 
better understand the impact of temperature on coagulation, the aPTT tests were 
performed at two different temperatures: typical endothermic body temperature (37°C) 
and hibernation temperature (3°C). To test at 37°C, the sample cuvette was allowed to 
incubate for 3 minutes following the addition of 100 microliters of plasma and 100 
microliters of Cephen 5 reagent. Measurement of coagulation time began following the 
3 minute incubation period and the addition of 100 microliters of calcium chloride 
reagent. To test at 3°C, the plasma samples, Cephen 5 reagent and calcium chloride 
reagent were all placed in an ice bath to keep them cold. The plasma sample and 
Cephen 5 reagent were added to the sample cuvette, and this mixture was kept in an ice 
bath for at least two minutes to ensure that it reached approximately 3°C. An infrared 
thermometer was used to measure the temperature of the sample. When the sample 
reached 3°C, it was placed into the analyzer and calcium chloride was added 
immediately to begin the coagulation time measurement. Once the sample had clotted, 
the temperature was measured again. These two temperature values were averaged to 
find the value for T1 in the equation for Q10, which was calculated using the formula 
. A one-way ANOVA was performed to determine potential statistical 
significance within the three groups for coagulation time at 3°C and 37°C and between 
the groups for Q10 value. 
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Changes in Coagulation Factor Levels 
Despite a drastic reduction in the rate of blood flow, frogs in hibernation still 
experience micro-tears in their vasculature, which would initiate coagulation via the 
intrinsic pathway. The aPTT test can provide information about the presence of factors 
VIII, IX, XI and XII in the hibernating frogs compared to the room temperature frogs. To 
determine whether some coagulation factors are down-regulated during hibernation, 
rescue assays were performed using factor-deficient human plasma. Twenty microliters 
of frog plasma was mixed with 80 microliters of reconstituted human plasma that is 
deficient in one factor of the intrinsic pathway. Then aPTT was used to assess the 
clotting time. If this combination clotted faster than the factor-deficient plasma by itself, 
then it has been “rescued” and the frog plasma sample can be concluded to contain that 
clotting factor in sufficient amounts. Failure to rescue the factor-deficient plasma 
indicates a lack of that factor. This method was used to determine the relative levels of 
factors VIII, IX, XI and XII in the room temperature and hibernating frogs. A one-way 
ANOVA was again used to determine statistical significance between the three groups 
for each coagulation factor. 
 
Presence of a Coagulation Inhibitor  
To determine the possibility of a coagulation inhibitor produced by hibernating 
frogs, aPTT was performed using 50 microliters room temperature plasma combined 
with 50 microliters hibernating plasma. If the addition of the hibernating plasma 
elongated the clotting time of the room temperature plasma, it would suggest the 
presence of a coagulation inhibitor in the hibernating plasma. The inhibitor could be a 
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protein, such as the α2-macroglobulin protein that is upregulated in ground squirrels 
during hibernation, or it could be another type of molecule such as a polysaccharide 
(carbohydrate) like heparin. To test this question, samples of hibernating plasma were 
placed in a water bath at 80°C for approximately one hour. If the inhibitor is a protein, 
the heat from the water bath would have resulted in denaturation, rendering the 
protein nonfunctional. If addition of the heated hibernating plasma to room 
temperature plasma did not elongate the coagulation time, it could be concluded that 
the inhibitor is a protein. One-way ANOVA was used to identify any statistical 
significance between the coagulation time of the room temperature plasma by itself and 
when it was mixed with hibernating and denatured hibernating plasma.  
 
Results 
Results from aPTT testing indicated that there was no significant difference 
(p=0.22) between the coagulation times of Group A, which had been at hibernation 
temperature for one week (61.64 ± 13.06 sec), Group B, which had been at hibernation 
temperature for three weeks (56.74 ± 11.09 sec), and Group C, which had been at 
hibernation temperature for the longest, at six weeks (56.11 ± 8.07 sec) [Fig. 3]. Because 
no significant difference occurred between these three groups, the data from all three 
were pooled for subsequent comparisons and analysis.  
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Figure 3 - Coagulation Times of Hibernating Groups A-C 
 
At both 3°C and 37°C, the hibernating frogs displayed elongated coagulation 
times (98.33 ± 31.34 sec at 3°C, 59.58 ± 11.48 sec at 37°C) when compared to the room 
temperature frogs (67.66 ± 20.85 sec at 3°C, 48.64 ± 11.23 sec at 37°C) [Fig. 4]. The 
difference between these groups was significant at both temperatures. 
 
Figure 4 - Coagulation Times at 3°C and 37°C 
(* indicates significant difference between 3°C and 37°C within sample group [p≤0.05]) 
(**indicates significant difference from room temperature frogs [p≤0.05]) 
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Effect of temperature on Coagulation 
The sheep plasma clotted faster than both frog groups at 37°C (38.10 ± 1.63 sec) 
and was greatly elongated at 3°C (98.62 ± 4.18 sec) [Fig. 4]. Calculation of Q10 values for 
these three groups showed that the coagulation time of sheep plasma was most 
impacted by the change in temperature (Q10= 0.651). The difference in Q10 between the 
room temperature frogs (Q10= 0.902) and hibernating frogs (Q10= 0.830) [Fig. 5] was not 
found to be statistically significant (p= 0.15).  
 
Figure 5 - Q10 Values 
(Groups with the same letter indicate no significant difference [p>0.05]) 
 
Changes in Coagulation Factor Levels 
Results from rescue assays indicated that coagulation factor VIII did not appear 
to be present in either room temperature frogs (81.37 ± 5.22 sec) or hibernating frogs 
(87.10 ± 4.17 sec), as both groups had longer coagulation times than the factor-deficient 
plasma by itself (76.77 ± 3.66 sec). Similarly, coagulation factor IX also did not appear to 
be present in either room temperature frogs (124.91 ± 7.66 sec) or hibernating frogs 
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(125.82 ± 7.75 sec), as both groups had longer coagulation times than the factor-
deficient plasma by itself (110.0 ± 4.0 sec) [Fig. 6].  
 
Figure 6 - Relative Coagulation Factor Levels 
(* indicates significant difference from room temperature [p≤0.05]) 
 
Coagulation factor XI was found to be present in sufficient amounts in the room 
temperature frogs (129.28 ± 20.89 sec) so as to rescue the factor-deficient plasma 
(166.84 ± 8.63 sec), but was not found in sufficiently high levels in the hibernating frogs 
(177.08 ± 9.30 sec) for rescue [Fig. 6]. These results indicate that coagulation factor XI is 
down-regulated in hibernating frogs, leading to a prolonged clotting time.  
The factor-deficient human plasma lacking coagulation factor XII did not clot at 
all during aPTT testing, but was rescued by both the room temperature frog plasma 
(61.38 ± 4.01 sec) and the hibernating frog plasma (73.81 ± 10.92 sec) [Fig. 6]. The 
difference between these two groups was shown to be statistically significant                
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(p= 0.0022), indicating that coagulation factor XII is also down-regulated during 
hibernation.   
 
Presence of Coagulation Inhibitor  
Results showed that when hibernating plasma was added to room temperature 
plasma, its clotting time was significantly elongated (from 48.64 ± 11.23 sec to 84.86 ± 
16.18 sec), which suggests that the hibernating plasma does, in fact, contain some kind 
of coagulation inhibitor. When the hibernating plasma was denatured in a hot water 
bath before being combined with the room temperature plasma, the coagulation time 
lengthened again (118.66 ± 23.45 sec) [Fig. 7], indicating that the inhibitor may not be a 
protein.  
 
Figure 5 - Quantification of Coagulation Inhibitor 
(* indicates significant difference from room temperature [p≤0.05]) 
 
 
 
 
 19 
Discussion 
Given that the physiological changes that accompany a process like hibernation 
are typically gradual, a stepwise progression of changes in the hemostatic properties of 
hibernating frogs was predicted. For example, that the frogs that were exposed to the 
cold temperature for the longest amount of time would be predicted to display the 
longest clotting time. However, this was not the case. While each group of hibernating 
frogs displayed elongated clotting times when compared to room temperature frogs, 
there was no significant difference in coagulation time between the frogs that were at 
hibernation temperature (3°C) for one week, three weeks, and six weeks. It seems that 
hibernating frogs need to make the necessary changes to their hemostatic system prior 
to reaching 3°C, indicating that the risk for coagulation at that temperature is the same 
regardless of the length of exposure. It would be beneficial to conduct future studies on 
the timing of hemostatic changes that focus on the span of time during which 
hibernation is being induced (period of time during which frogs go from 25°C to 3°C). 
This is likely the time in which the majority of physiological changes occur to prepare the 
animal for entering an extended period of dormancy.  
 
Effect of Temperature on Coagulation 
One factor that is known to elongate clotting in hibernating endotherms is 
decreased temperature because the enzymes of the coagulation cascade cannot work 
as efficiently at lower temperatures. However, given that endothermic animals 
experience a very narrow range of internal temperatures, we would expect that 
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hemostasis in this group would be much more impacted by the change in temperature 
than would be the case for ectotherms, who naturally experience a much greater range 
of internal temperatures. Indeed, at 37°C, the sheep plasma clotted quickly and 
efficiently, because this is typical endothermic body temperature, but at 3°C, a 
temperature that a sheep would never actually reach in nature, the clotting time 
increased dramatically. While both frog groups showed elongated clotting at 3°C 
compared to 37°C, the difference was less extreme than in sheep. This difference in the 
ability of enzymes, in this case the coagulation factors of the intrinsic pathway, to 
function at these two temperatures can be illustrated by the temperature coefficient, or 
Q10 value. A Q10 value equal to one would indicate no change in enzyme rate as 
temperature increases, whereas a Q10 value equal to two would mean that for a 10 
degree increase in temperature, the rate of the enzymatic reaction would increase 
twofold, and so on.  
In this study, it was found that the Q10 values for all groups were less than one, 
which would indicate that as temperature increased the rate of the enzymatic reaction 
decreased. This is somewhat counterintuitive because of the nature of the enzymatic 
reactions involved in coagulation. When the temperature is increased, the coagulation 
factors behave as enzymes typically do and perform their function more quickly 
(meaning the enzymatic rate increases), which would typically give a Q10 value greater 
than one. However, because the clotting enzymes are working faster, this subsequently 
causes coagulation to occur more rapidly and the overall rate of the reaction that can be 
measured actually decreases. This gives a Q10 value that is less than one. Due to this 
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counterintuitive relationship, the Q10 value can be thought of as the factor by which the 
enzyme function changes as the temperature decreases, rather than increases.  
If the hypothesis that endotherms are more impacted by temperature than 
ectotherms is correct, we would expect that the sheep plasma would display a Q10 value 
further away from one in either direction. Indeed, sheep displayed a Q10 value of 0.651, 
while room temperature and hibernating frogs displayed values of 0.902 and 0.830 
respectively. In essence, when the temperature dropped 10 degrees, the sheep’s 
enzymes performed at only about 65% of the speed that they did at the higher 
temperature, whereas the frogs’ enzymes performed at 90% and 83% of their original 
speed. Therefore, it can be concluded that changing temperature does, in fact, impact 
coagulation in ectotherms, but to a lesser degree than it does in endotherms. 
Additionally, the difference in Q10 values between room temperature and hibernating 
frogs was not found to be significant, which indicates that the difference in coagulation 
times between these groups cannot be solely attributed to the change in temperature. 
Hibernating frogs must employ other of biological mechanisms to account for their 
elongated clotting times.  
 
Changes in Coagulation Factor Levels 
Research has shown that some hibernating endotherms alter the levels of 
coagulation factors in their blood, effectively reducing their ability to initiate clotting. 
This study indicates that hibernating frogs employ the same technique. The factors that 
were examined were those of the intrinsic pathway (VIII, IX, XI and XII) as this is the 
“internal” pathway that would typically initiate clotting during hibernation. It is 
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suspected that both factor VIII and factor IX are absent in both room temperature and 
hibernating frogs, because neither sample rescued the factor-deficient human plasma 
and enabled it to clot. The reason that frogs appear to lack these two factors completely 
is not entirely known. The coagulation cascade may not be a system that has been 
completely conserved throughout vertebrate evolution. Perhaps factors VIII and IX 
evolved later, with the development of mammals. Alternatively, perhaps frogs do have 
factors that perform the same role in coagulation, but they are sufficiently different 
from those of humans such that they would not be able to rescue human plasma. Future 
studies are required to address this question.  
Results do indicate that hibernating frogs alter the levels of the other two 
intrinsic coagulation factors, factor XI and factor XII, somewhat like an induced 
hemophilia. It appears as though the production of factor XI may be completely shut off 
in hibernators, given that the hibernating plasma was unable to rescue the factor-
deficient plasma. On the other hand, human plasma deficient in factor XII  was rescued 
by both room temperature and hibernating frog plasma, indicating that this factor may 
still be produced in hibernators but to a lesser degree. By down-regulating the 
production of these factors during hibernation, the initiation of hemostasis takes longer 
and the frogs can preemptively protect themselves against the increased risk of clotting 
due to sluggish blood flow.  
 
Presence of a Coagulation Inhibitor 
Certain endotherms have also been shown to produce an inhibitor as a means to 
prevent coagulation during hibernation, such as the protein α2-Macroglobulin or the 
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polysaccharide heparin. It is reasonable to expect that ectotherms may employ a similar 
strategy during hibernation. Given that the addition of hibernating plasma to a sample 
of room temperature plasma increased the coagulation time, it appears as though the 
plasma of hibernating frogs does contain some kind of inhibitor. Results from the rescue 
assays provide additional evidence for this hypothesis. If there was no inhibitor present, 
it would be expected that the clotting time of the factor-deficient human plasma would 
remain unchanged following the addition of a frog plasma sample if that sample did not 
contain the missing factor. However, for factors VIII, IX, and XI, in which the hibernating 
plasma did not rescue the factor-deficient plasma, the clotting time is actually slightly 
longer than the factor-deficient plasma alone. This elongation is likely due to the 
presence of an inhibitor. 
Although the macromolecular class of this inhibitor remains unknown, results 
from this study indicate that it does not appear to be a protein. If it were a protein, one 
would expect that heating the hibernating plasma sample would cause denaturation 
and destroy its inhibitory ability, thereby causing the clotting time to decrease when 
compared to unheated hibernating plasma. Results showed that the addition of 
denatured hibernating plasma actually increased the clotting time further. This 
observed elongation may be due to the fact that the water bath would denature the 
coagulation enzymes as well, and the sample became sufficiently diluted that the 
remaining functional enzymes from the room temperature plasma were less efficient at 
clotting the sample. If this is true, it could be possible that the inhibitor is actually a 
protein, but that the loss of its anti-coagulatory function is masked by the loss of the 
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coagulatory function of the clotting factors. It would be beneficial to conduct future 
studies using varying ratios of room temperature and hibernating plasma to better 
understand what role dilution may play in these results.  
 
Conclusion 
The purpose of this study was to determine whether ectothermic regulation of 
hemostasis during hibernation is similar to that of endotherms, and results indicate that 
these groups do in fact use similar physiological mechanisms. The American bullfrog 
displays a down-regulation of certain coagulation factors during hibernation as well as 
the production of a coagulation inhibitor, both of which are strategies employed by 
hibernating endotherms. Ectotherms, however, are less impacted by the reduction in 
temperature accompanying hibernation than are endotherms, and the change in 
temperature could not account for the difference in clotting times between hibernating 
and non-hibernating frogs, creating the need for such physiological mechanisms to 
prolong coagulation.   
This study does face some limitations, such as the limited sample of frogs from 
which plasma was drawn and the fact that the rescue assays were performed using 
factor-deficient human plasma, which may not be entirely comparable to frog plasma. 
Additionally, amphibians such as the American bullfrog represent only one class of 
animals in the large and diverse group of ectotherms, and therefore cannot be assumed 
to represent all ectothermic animals as a whole. Additional studies are needed to better 
understand the progression and timing of these hemostatic changes when hibernation is 
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being induced, and to determine the identity of the coagulation inhibitor. Despite these 
limitations and the need for future research, this study provides valuable insight into 
how hibernation affects hemostasis in ectotherms, a group for which little was 
previously known.         
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